Fousseyni Traore1*, Belco Maiga1, Konimba Diabaté2, Yacaria Coulibaly3, Hawa Diall1, Pierre Togo1, Oumar Coulibaly1, Issa Amadou3, Karamoko Sacko1, Abdoul Karim Doumbia1, Abdoul Aziz Diakite1, Bakary Kamaté4, Fatoumata Dicko-Traoré1, Mariam Sylla1, Boubacar Togo1
1Gabriel Toure hospital, department of pediatrics, Bamako-Mali
2National hospital of Mali, Radiation therapy service, Bamako-Mali
3Gabriel Toure hospital, pediatric surgery service, Bamako-Mali
4Hospital of Point G, department of histopathology, Bamako-Mali
Purpose: Congenital mesoblastic nephroma (CMN) is a mesenchymal renal tumor of the newborn and young infant. This tumor is generally non-aggressive and amenable to surgical removal. Few studies are available in Africa about the treatment of CMN. The aim of this retrospective study was to evaluate the treatment of CMN in the pediatric oncology unit of teaching hospital Gabriel Toure in Bamako-Mali.
Patients and method: The study was performed retrospectively from 01 January 2005 to 31 December 2016 (duration 11 years), in the pediatric-oncology unit of Gabriel Touré Teaching Hospital. Were included, patients with histologically proven CMN. The uretero-nephrectomy was indicated for all included patients. Patients with significant tumor volume at abdominal CT-scan and those with no staging at surgery with imprecise histologic stage, received neoadjuvant and adjuvant chemotherapy, respectively.
Result:From 2005/01/01 to 2016/12/31 eight cases of CMN were included in the study. CMN accounted for 3% of renal tumors. The median age of patient was 4.5 months (1 month-6 months) with a sex ratio of 0.33 (M = 2, F = 6). Abdominal mass was the most common physical sign (n = 7; 87%). The CT scan was performed in five patients (62%). There was no difference in laterality (right kidney, n = 4, left kidney, n = 4).
Three patients received neoadjuvant chemotherapy (37%). Seventy-two percent of patients received initial nephro-ureterectomy. The histology confirmed CMN in all patients (n = 8, 100%). All patients had the classic histological form (n = 8; 100%). Stage 1 (n = 4; 50%), stage 2 (n = 2; 25%), unspecified (n = 2; 25%). Two patients received adjuvant chemotherapy (25%). Overall survival was 100% with a median follow-up of 8 years (6 -10 years).
Conclusion: Multidisciplinary collaboration is the key of therapeutic success of CMN.